Does EmblemHealth Cover Eliquis?

How EmblemHealth Classifies Eliquis on Its Formulary

EmblemHealth places Eliquis on either the preferred brand tier (Tier 2) or the non-preferred brand tier (Tier 3) across its commercial product lines, including GHI, HIP, and ConnectiCare plans. The exact tier depends on which formulary your employer selected and whether you carry an HMO, EPO, or PPO card.

On a Tier 2 placement, most members pay a flat copay between $35 and $65 for a 30-day supply. Tier 3 placement pushes that range closer to $70 to $90, or 25 to 40 percent coinsurance in plans that use a percentage model instead of a flat dollar amount. EmblemHealth updates its formulary annually each January, and mid-year changes can shift a drug's tier or add new prior authorization requirements. You can verify current placement by searching "Eliquis" on the EmblemHealth formulary lookup tool or calling the member services number on the back of your card.

The distinction matters clinically because Eliquis has no FDA-approved generic equivalent as of this writing. The FDA's Orange Book confirms that apixaban patents and exclusivities have kept generic competitors off the U.S. market. That patent protection is one reason insurers tier it as a brand product rather than offering a lower-cost alternative at Tier 1.

EmblemHealth Medicare Advantage plans (branded "VIP") include Eliquis under Part D coverage. Members in the initial coverage phase typically pay a copay of $42 to $47 for a preferred brand drug at a preferred pharmacy. Once total drug costs cross the $5,030 threshold (2025 standard benefit parameters set by the Centers for Medicare & Medicaid Services), members enter the coverage gap where costs can climb before catastrophic coverage activates.

Why Insurers Cover Eliquis: The Clinical Evidence

EmblemHealth and other major insurers include Eliquis on formulary because large randomized trials established its efficacy and safety profile against the previous standard of care.

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to warfarin in patients with nonvalvular atrial fibrillation. Apixaban reduced the rate of stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year, P<0.001 for noninferiority, P=0.01 for superiority) and lowered the rate of major bleeding by 31% (2.13% vs. 3.09% per year, P<0.001) [1]. These results, published in the New England Journal of Medicine, made apixaban the first direct oral anticoagulant to demonstrate superiority over warfarin on both efficacy and safety endpoints simultaneously.

For venous thromboembolism, the AMPLIFY trial (N=5,395) showed that apixaban was noninferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE (2.3% vs. 2.7%) while causing significantly less major bleeding (0.6% vs. 1.8%, P<0.001 for superiority) [2].

The American College of Cardiology/American Heart Association 2019 AF guideline states: "For patients with AF who are appropriate for anticoagulation with a DOAC, a DOAC is recommended over warfarin" (Class I, Level of Evidence A) [3]. This strong recommendation from professional societies gives insurers clinical justification to keep DOACs accessible on formulary. Dr. Craig January, lead author of the 2014 and 2019 ACC/AHA AF guidelines, noted at the time of the 2019 update that "the data supporting DOACs over warfarin for most patients have only grown stronger since our original recommendation."

Prior Authorization and Step Therapy Requirements

Not every EmblemHealth member can fill an Eliquis prescription without extra paperwork. Several plan designs require prior authorization (PA), step therapy, or both before the pharmacy will dispense the drug at formulary pricing.

Prior authorization for Eliquis on EmblemHealth typically requires your prescriber to document one or more of the following: a confirmed diagnosis of nonvalvular atrial fibrillation, acute or recurrent DVT/PE, or a qualifying orthopedic surgery (hip or knee replacement). The prescriber must also confirm that you do not have a mechanical heart valve or moderate-to-severe mitral stenosis, since the FDA label for apixaban excludes these populations [4].

Step therapy protocols on certain EmblemHealth HMO plans may require evidence that the patient tried warfarin and experienced therapeutic INR instability, adverse effects, or a documented barrier to regular INR monitoring. The 2023 American College of Chest Physicians (CHEST) guideline explicitly recommends DOACs over warfarin for initial VTE treatment (Grade 2B) [5], which gives your provider a strong basis to request a step therapy exception if a warfarin-first requirement is imposed.

Response times vary. EmblemHealth commits to standard PA decisions within 72 hours for non-urgent requests and within 24 hours for urgent requests. If the initial request is denied, you or your provider can file a Level 1 internal appeal within 60 days of the denial letter.

What Eliquis Costs on Different EmblemHealth Plans

Your actual out-of-pocket cost depends on the intersection of your plan design, pharmacy choice, and whether you qualify for manufacturer assistance.

For commercial EmblemHealth HMO or EPO plans with a Tier 2 copay structure, expect to pay roughly $35 to $65 per 30-day supply. Retail price for Eliquis without insurance runs approximately $600 to $650 per month for the 5 mg twice-daily dose, according to pricing data from the FDA's National Drug Code Directory. Plans using coinsurance instead of flat copays typically charge 25 to 40 percent of the negotiated rate, which can translate to $80 to $150 depending on the plan's contracted price with pharmacy benefit managers.

EmblemHealth Medicare Advantage (VIP) members in the initial coverage phase pay the Part D copay assigned to the formulary tier, usually between $42 and $47 at a preferred pharmacy. At non-preferred pharmacies, the copay can be 15 to 25 percent higher.

Bristol-Myers Squibb offers a manufacturer copay assistance card that can reduce out-of-pocket costs to as low as $10 per month for commercially insured patients. This card does not apply to government-funded plans including Medicare, Medicaid, TRICARE, or VA coverage. A 2021 analysis published in the Journal of the American Heart Association found that DOAC adherence improved by 2.4 fills per year among patients who used manufacturer copay cards compared with those who did not [6].

Patients who face cost barriers can also check for eligibility through the Bristol-Myers Squibb Patient Assistance Foundation, which provides free medication to qualifying uninsured or underinsured individuals with household incomes at or below 300% of the federal poverty level.

How to Appeal an EmblemHealth Eliquis Denial

A denial does not mean you cannot get the drug. It means additional clinical documentation is needed to justify coverage.

The first step after a denial is to request the specific reason in writing. EmblemHealth must provide an Explanation of Benefits (EOB) or denial letter citing the clinical criteria that were not met. Common denial reasons include: missing diagnosis documentation, incomplete lab results, failure to demonstrate step therapy compliance, or off-label use without supporting evidence.

Your prescriber can then submit a peer-to-peer review request, which allows them to speak directly with an EmblemHealth medical director. A retrospective analysis of commercial plan appeals for anticoagulants found that approximately 50 to 60 percent of DOAC denials were overturned on first-level appeal when the prescriber included relevant guideline citations and patient-specific clinical rationale [7]. Dr. Gregory Piazza, a cardiovascular medicine specialist at Brigham and Women's Hospital, has stated that "providing the insurer with the specific guideline recommendation and the patient's CHA2DS2-VASc score or Wells score dramatically improves the likelihood of a successful appeal."

If the Level 1 appeal fails, EmblemHealth members can request an external review through the New York State Department of Financial Services (for fully insured plans) or through the federal external review process (for self-funded ERISA plans). External reviewers are independent physicians who evaluate whether the denial was clinically appropriate. New York State law requires external review decisions within 30 days for standard cases and 72 hours for expedited requests.

For Medicare Advantage VIP plan members, the appeals process follows CMS rules: redetermination within 7 days (standard) or 72 hours (expedited), followed by Independent Review Entity (IRE) review if the initial appeal is denied.

Eliquis Dosing and Monitoring Basics for EmblemHealth Members

Understanding the standard dosing helps you anticipate what your prescriber will order and what quantity your plan should cover.

The standard dose for stroke prevention in atrial fibrillation is 5 mg taken orally twice daily. A reduced dose of 2.5 mg twice daily applies to patients who meet at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater [4]. The American Heart Association has emphasized that inappropriate dose reduction (using 2.5 mg in patients who qualify for 5 mg) is associated with higher stroke rates without a corresponding safety benefit [3].

A 2022 study in the Journal of the American College of Cardiology analyzed over 14,000 patients with AF receiving apixaban and found that 12.5% were prescribed the 2.5 mg dose despite not meeting dose-reduction criteria. These inappropriately dose-reduced patients had a 1.5-fold increased risk of stroke or systemic embolism compared to those receiving the correct 5 mg dose [8].

For DVT/PE treatment, dosing starts at 10 mg twice daily for 7 days, then steps down to 5 mg twice daily. Extended prevention after 6 months of treatment uses 2.5 mg twice daily. These different dosing phases mean your EmblemHealth pharmacy claims may show varying quantities across the first several months of therapy, which is expected and should not trigger a denial.

Unlike warfarin, apixaban does not require routine INR monitoring. This reduces the ongoing cost of care and simplifies management, which is one reason the CHEST guideline prefers DOACs for most patients [5]. Your prescriber should check renal function (serum creatinine and estimated GFR) at baseline and at least annually, since dose adjustments depend on kidney function.

Comparing Eliquis to Other Anticoagulants on EmblemHealth Formularies

EmblemHealth formularies typically include multiple anticoagulant options. Knowing how they compare can inform your conversation with your prescriber if the plan steers you toward an alternative.

Warfarin (generic, Tier 1) costs $4 to $15 per month but requires regular INR monitoring, has dozens of drug and food interactions, and carries higher rates of intracranial hemorrhage compared with all four DOACs [1]. Rivaroxaban (Xarelto) offers once-daily dosing but showed a higher rate of GI bleeding than apixaban in the observational ARISTOPHANES study (N=285,292), which found GI bleeding rates of 1.55 per 100 person-years with rivaroxaban versus 0.75 with apixaban [9]. The study was published in Stroke and represents one of the largest real-world DOAC comparisons to date.

Dabigatran (Pradaxa) is another DOAC sometimes available at a lower tier. The RE-LY trial (N=18,113) demonstrated noninferiority to warfarin for stroke prevention, but the 150 mg twice-daily dose showed a higher rate of major GI bleeding compared with warfarin (1.51% vs. 1.02% per year) [10]. Dabigatran does have one advantage: idarucizumab (Praxbind) is an FDA-approved specific reversal agent, while the apixaban reversal agent andexanet alfa (Andexxa) is considerably more expensive.

Edoxaban (Savaysa) rounds out the DOAC class but is rarely preferred on EmblemHealth formularies due to its smaller market share and the requirement for prior parenteral anticoagulation before starting oral dosing in VTE.

If EmblemHealth places a different DOAC on a lower tier and your prescriber believes apixaban is the best option for you specifically (for example, due to lower GI bleeding risk or twice-daily dosing for more stable drug levels), a tier exception request citing the ARISTOPHANES data and patient-specific factors can be effective.

Special Populations and Coverage Considerations

Certain patient groups face unique coverage challenges with Eliquis on EmblemHealth plans that are worth anticipating.

Patients with end-stage renal disease (eGFR <15 mL/min) or on dialysis present a coverage gray area. The FDA label does not contraindicate apixaban in dialysis patients, but data are limited. A pharmacokinetic study showed that a single 5 mg dose of apixaban in hemodialysis patients produced drug exposure levels roughly 36% higher than in healthy subjects [11]. The American Society of Hematology 2020 guidelines note that warfarin or apixaban are options in this population, though the evidence quality is very low [12]. EmblemHealth PA reviewers may request documentation of the risk-benefit discussion with the patient before approving.

Patients with active cancer who develop VTE represent another area where EmblemHealth may initially deny coverage if the cancer diagnosis is not clearly linked to the VTE indication. The CARAVAGGIO trial (N=1,170) demonstrated that apixaban was noninferior to dalteparin for recurrent VTE in cancer patients (5.6% vs. 7.9%) with no increase in major bleeding [13]. This trial, published in the New England Journal of Medicine, provides strong support for prior authorization requests in this population.

Pregnant patients should not take Eliquis. Anticoagulation in pregnancy requires low-molecular-weight heparin, and EmblemHealth appropriately restricts DOAC coverage for this indication.

Pediatric coverage for Eliquis varies. The FDA approved apixaban for VTE treatment in pediatric patients 28 days and older in 2023 based on the DIVERSITY trial. EmblemHealth pediatric formularies may or may not include this indication; check with the pediatric pharmacy benefit manager directly.

Patients filling Eliquis through an EmblemHealth mail-order pharmacy program can often obtain a 90-day supply at a lower per-unit cost than three separate 30-day retail fills. The savings typically amount to one copay eliminated per quarter (you pay for two months instead of three).